• Earlier this year, Novavax reported quarterly results that exceeded analyst expectations for both earnings per share and revenue, even though revenue fell compared with the prior year.
• At the same time, the company expanded use of its Matrix-M adjuvant by licensing it to Pfizer for up to two vaccine candidates and by signing additional material transfer agreements with other drug makers.
• We’ll now examine how the new Pfizer Matrix-M license and related collaborations may reshape Novavax’s investment narrative and potential revenue mix.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Novavax Investment Narrative Recap

To own Novavax today, you need to believe its protein-based platform and Matrix-M adjuvant can support a durable, partner-driven vaccine business rather than a one-product COVID story. The new Pfizer Matrix-M license strengthens that thesis by adding another potential royalty and milestone stream, but it does not remove the near term catalyst of proving that partner-led launches can translate into steadier revenue, nor the key risk around dependence on external partners for commercialization and timely milestones.

The Pfizer agreement, which brought in a US$30 million upfront payment for up to two vaccine candidates, is the clearest recent example of Novavax trying to broaden its revenue mix beyond direct COVID vaccine sales. It links the company’s short term story to the success of Matrix-M across multiple indications and partners, which could help offset volatility if COVID demand is weaker than hoped, but it also increases the importance of how effectively partners advance these programs.

Yet, despite this progress, you should still be aware that partner delays or weaker uptake could...

Novavax’s narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts painted a far harsher picture, assuming revenue could fall about 25 percent a year and that Novavax might still not be profitable within three years, while others point to Matrix-M licensing as a possible buffer; this new Pfizer deal could shift both views over time, so it is worth comparing these very different expectations before you decide how you see the story.

Explore 3 other fair value estimates on Novavax - why the stock might be worth over 5x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.